Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB control number

_	Substitute fo	or form 1449B/PTC)		Complete if Known		
	INFORMATION DIGGLOCURE				Application Number	10/556,224	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing Date	September 27, 2006	
					First Named Inventor	Martin HENDRIX, et al.	
					Art Unit	1624	
(Use as many sheets as necessary)					Examiner Name	Susanna Moore	
_	Sheet	1	of	1	Attorney Docket Number	01-2116	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
/S.M./		WUNDER, F. et al. "Characterization of the First Potent and Selective PDE9 Inhibitor Using a cGMP Reporter Cell Line" Molecular Pharmacology 68(6):1775-1781 (2005).	

Examiner Signature	/Susanna Moore/	Date Considered	01/14/2010	
-----------------------	-----------------	--------------------	------------	--

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicants unless classed extensions on unpuble reloising." Applicants unless citation designation number forcionant." Applicants unless citation designation number forcionant." Applicants unless citation designation for unpublication designation number forcionant." Applicants unless citation designation for unpublication designation number forcionant."

^{&#}x27;Applicant's unique obtained nesignation number (opinons). 'Applicant is to place a check mark here if English Inanguage Translation is attached This collection of Inormation is required by 37 CPR 19.8. The information is required to obtain or relation a benefit by the public which is to life and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CPR 1.14. This collection is estimated to take? Prours to comprise, recluding gathering preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the and/usula case Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patert and Trademark CIDE. U.S. Department of Commence, P.O. Sox 1450, NextSex, Av. 2231-1450. DNOT STEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, NextSex 1450, Next 2014 of Paterts of Pate